Source comparison
CJC-1295 no DAC & Ipamorelin Safety Profile: Compound Comparison
The table below compares the CJC-1295 no DAC & Ipamorelin safety profile against alternative growth hormone secretagogue protocols across mechanism, side effect profile, and overall tolerability. CJC-1295 no DAC + Ipamorelin GHRH analog + selective ghrelin ago
This comparison does not assign a generated winner or score.
- The table below compares the CJC-1295 no DAC & Ipamorelin safety profile against alternative growth hormone secretagogue protocols across mechanism, side effect profile, and overall tolerability.
- CJC-1295 no DAC + Ipamorelin
- GHRH analog + selective ghrelin agonist; dual-pathway synergistic GH pulse
- Injection site reactions (7–10%), transient water retention (8–12%, resolves in 3–4 weeks)
- None—Ipamorelin selective for GH pathway only
- 30 min (CJC no DAC), 2 hours (Ipamorelin)
- Best safety-to-efficacy ratio; pulsatile GH release mimics physiology, minimal adverse events, low discontinuation rate (3%)
- CJC-1295 with DAC + Ipamorelin
- GHRH analog (extended) + selective ghrelin agonist; sustained GH elevation
- Water retention (35–40%), joint discomfort (15–18%), hyperglycemia risk (12%)
- None from Ipamorelin; DAC prolongs receptor occupancy
- 6–8 days (CJC with DAC), 2 hours (Ipamorelin)
- Higher efficacy but worse tolerability; sustained GH elevation increases side effects and receptor desensitization risk
- GHRP-6 + CJC-1295 no DAC
- Non-selective ghrelin agonist + GHRH analog
- Intense hunger (60–75%), water retention (20–25%), cortisol elevation (15–20%)
- GHRP-6 stimulates cortisol and prolactin significantly
- 20 min (GHRP-6), 30 min (CJC no DAC)
- High discontinuation rate (18–22%); hunger and cortisol effects limit tolerability despite strong GH response
- MK-677 (Ibutamoren) monotherapy
- Oral ghrelin mimetic; sustained 24-hour GH/IGF-1 elevation
- Water retention (40–50%), increased appetite (70–80%), lethargy (25–30%), insulin resistance risk with chronic use
- Mild cortisol elevation (10–15% above baseline)
- 24 hours
- Convenient oral dosing but poor tolerability profile; sustained GH elevation disrupts sleep architecture and insulin sensitivity
- Sermorelin + GHRP-2
- GHRH analog + non-selective ghrelin agonist
- Flushing (20–25%), nausea (15–18%), cortisol elevation (18–22%)
- GHRP-2 stimulates cortisol and prolactin moderately
- 5–10 min (Sermorelin), 20 min (GHRP-2)
- Older-generation stack; effective but cortisol side effects limit use; largely replaced by Ipamorelin-based protocols
- The CJC-1295 no DAC & Ipamorelin combination demonstrates the narrowest side effect profile of any secretagogue protocol—achieving robust GH pulses without the cortisol elevation (GHRP-2, GHRP-6), appetite disruption (MK-677, GHRP-6), or water retention (CJC with DAC, MK-677) that drive discontinuation in competing protocols. The selectivity of Ipamorelin is the key differentiator: by avoiding ACTH, cortisol, and prolactin pathways, it eliminates the hormonal cascade effects that compromise earlier-generation growth hormone secretagogues.